At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned Swiss biopharmaceutical company, we’re driven by science, but above all, by the people behind every treatment — the patients and their families.
Through our unique “development only” model, we bring forward promising therapies and transform them into treatments that can reach those who need them most, faster.
Are you passionate about advancing science and improving lives? We are currently looking for a driven, passionate and collaborative professional to join our Biostatistics and Data Management department based at our Headquarters in Lausanne, Switzerland as
Permanent role | Location: Lausanne, Switzerland
As a Senior Clinical Data Manager, you will be accountable for the quality and timelines of data management activities across assigned clinical studies. You will play a pivotal role in ensuring that complete, accurate, and consistent clinical data is available to support our internal decision-making processes. Whether managing internal tasks or overseeing activities outsourced to external providers, you are the guardian of data integrity and quality.
Requirements
Benefits
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com.
Please contact our HR Department prior to submitting any profiles. We cannot accept unsolicited applications from agencies or recruiters.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe.
Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections.
Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®
If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!